Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: John L. who wrote (982)	6/2/1998 11:39:00 PM
From: Stephen How	Respond to of 1432

I missed this point: (from mesaone's posting of Crossen's report: siliconinvestor.com The WSJ article stated that hextend failed to show an advantage over hespan and that additional studies in an ad hoc fashion are being planned to accentuate advantages but this may be too little too late. in this small study, 41% of patients did not get transfused. therefore, the patients who received blood transfusions were an especially small group and yet, in this group , the hextend patients experienced one liter less blood loss than the hespan patients (p<.03 in this small group). much more interestingly, every variable related to blood loss went in the same direction in favor of hextend. this includes fewer red blood cells transfused, less fresh frozen plasma used, less platelets used and less calcium transfused. The p=.03 for blood loss between the transfusion patients of the Hextend&reg and hetastarch groups is statistically significant. (Extex on the Motley Fool board posted a miswording of this Crossen statement, and I argued that the 1 L EBL difference was not a valid conclusion. However, the direct Crossen wording says that the results are SS!) I'm pretty sure the p=.03 takes into account the small N. If this analysis is correct, I think that the p will decrease further for larger N! I'm suprised that Biotime did not issue a press release on this analysis of the data. If true, this analysis is extremely important news, and clearly shows Hextend&reg's superiority over hetastarch. I will change my mind if this is true. Steve btim.dyn.ml.org

To: John L. who wrote (982)	6/3/1998 12:58:00 PM
From: mesaone	Read Replies (1) \| Respond to of 1432

I don't think that Baxter's pulling the plug on their blood substitute product will have any affect on BTIM. Hextend is not a blood substitute and does very different things than a blood substitute. If this has any affect on BTIM it will only be because some people are still misinformed about what Hextend is... but for the most part, everyone is pretty informed about the differences here. I remain long on BTIM and I agree.. it would be nice to see the upswing so our portfolios don't look so bloody red. I also wish that BTIM did a much better job of investor relations.. no, let me clarify that.. did ANY job at investor relations. I think that the longs should start grumbling more to the company and not to the short sellers. The company needs to pay attention to our needs. So far they tend to just ignore us. I think we need to be much more vocal in our dissatisfaction with the way they handle PR. After all.. if they did their job I wouldn't had to put up a web site to help them out. I am getting pretty annoyed at their silence. I can understand that they don't want to jeopardize the FDA approval process... but we're taking a beating and they have turned their backs. I understand that Victoria Bellport said they had a PR firm... well... Victoria.. what are they doing about Investor Relations??? Remember, we are the people who own the company too. I think you should come out of your ivory tower and faces the masses.